Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8903952 | 0.84 | TDP1 (0.44) | TDP1ATMRAB9AALDH1A1MAPT | |
| SCHEMBL8901768 | 0.83 | TDP1 (0.44) | TDP1ATMRAB9AALDH1A1MAPT | |
| SCHEMBL8902192 | 0.83 | TDP1 (0.44) | TDP1ATMRAB9AALDH1A1MAPT | |
| SCHEMBL8903509 | 0.81 | TDP1 (0.47) | TDP1ATMRAB9AALDH1A1MAPT | |
| SCHEMBL18318470 | 0.79 | TDP1 (0.51) | TDP1ATMRAB9AALDH1A1MAPT | |
| SCHEMBL9755756 | 0.73 | SMN1; SMN2 (0.40) | ALDH1A1MAPTHPGDPOLBSMN1; SMN2 | |
| SCHEMBL8901788 | 0.71 | MAPT (0.37) | TDP1ATMMAPTHTT | |
| SCHEMBL8901817 | 0.71 | HTT (0.48) | TDP1ATMRAB9AALDH1A1MAPT | |
| SCHEMBL8902384 | 0.70 | HTT (0.42) | TDP1ATMRAB9AALDH1A1MAPT | |
| SCHEMBL8902582 | 0.70 | HTT (0.42) | TDP1ATMRAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5593970-A | ANTITUMOR AND ANTCARCINOGENIC AGENTS; TRETMENT OF CANCEROUS BONE MARROW BEFORE REGRAFTING | BIOCHEM PHARMA INC. (CA) | 1997-01-14 | — | — | US | disclosed |